Effect of Compound Danshen Dripping Pills combined with Rosuvastatin on left ventricular remodeling and myocardial fibrosis in patients with acute myocardial infarction after percutaneous coronary intervention
XU Xiaojin ZHANG Yiyan ZHANG Sujie GONG Juexiao LOU Bin GU Minglin YU Shengyong
Department of Cardiovascular, Jiangsu Province Academy of Traditional Chinese Medicine, Jiangsu Province, Nanjing 210028, China
Abstract:Objective To investigate the effects of Compound Danshen Dripping Pills combined with Rosuvastatin on left ventricular remodeling (LVR) and myocardial fibrosis in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods Eighty patients with AMI who underwent PCI surgery in Jiangsu Province Academy of Traditional Chinese Medicine from January 2015 to June 2018 were selected and divided into observation group and control group according to the random number table method, with 40 cases in each group. Both groups were given routine treatment after operation, and control group was treated with Rosuvastatin, while observation group was treated with Compound Danshen Dripping Pills on the basis of control group. Clinical effect, traditional Chinese medical syndrome score, echocardiography index, laboratory index before and after treatment and adverse drug reactions were compared between two groups. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). After treatment, traditional Chinese medical syndrome scores of two groups were significantly lower than those before treatment, and observation group was lower than control group (P < 0.05). After treatment, left ventricular ejection fraction of two groups was significantly higher than that before treatment, and observation group was higher than control group (P < 0.05). After treatment, left ventricular end diastolic dimension and left ventricular end systolic diameter in two groups were significantly smaller than those before treatment, and observation group was smaller than control group (P < 0.05). After treatment, levels of matrix metalloproteinases-9, transforming growth factor-β1 and connective tissue growth factor in two groups were lower than those before treatment, and observation group was lower than control group (P < 0.05). During the treatment, there was no obvious adverse reaction in both groups. Conclusion The combination of Rosuvastatin and Compound Danshen Dripping Pills can effectively improve the clinical symptoms of AMI patients after PCI, and delay the progression of LVR and myocardial fibrosis.